$BACK News

IMAC Hldgs Q3 EPS $(1.15) Up From $(1.71) YoY, Sales $21.223K Down From $56.300K YoY

Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers

IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery

IMAC Hldgs Q1 EPS $(1.08) Down From $(0.39) YoY, Sales $1.500K

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Ignite Proteomics, Subsidiary Of IMAC Holdings, Announces MHC-II Expression As Superior Predictor For Pembrolizumab Response Compared To PD-L1 Ahead Of NCCN Conference

Ignite Proteomics, Subsidiary Of IMAC Holdings, Announces MHC-II Expression As Superior Predictor For Pembrolizumab Response Compared To PD-L1 Ahead Of NCCN Conference

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

IMAC Holdings launches Ignite Proteomics subsidiary

Imac Holdings Faces Compliance Challenge and Delisting Risk

IMAC Holdings receives noncompliance notification from Nasdaq

IMAC Holdings receives notification of deficiency from Nasdaq

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

DayDayCook Names Jeffrey Ervin as Co-Chief Financial Officer

DDC Enterprise appoints Jeffrey Ervin as co-CFO